Research programme: cytomegalovirus vaccines - PfizerAlternative Names: Cytomegalovirus reVLPs®; Cytomegalovirus VLPs - Redbiotec; RBT 301; RBT 302; RBT 303; RBT 304; RBT 305; RBT 306
Latest Information Update: 19 Jul 2016
At a glance
- Originator Redbiotec; Redvax
- Developer Pfizer
- Class Virus-like particle vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cytomegalovirus infections